Stockscreener 앱 받기
22.29
2.39%
0.52
시간 외 거래:
22.29
전일 마감가:
$21.77
열려 있는:
$21.72
하루 거래량:
1.33M
Relative Volume:
1.56
시가총액:
$2.39B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-10.37
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
-5.55%
1개월 성능:
-13.27%
6개월 성능:
+30.20%
1년 성능:
+8.89%
1일 변동 폭
$21.58
$23.24
1주일 범위
$20.40
$23.75
52주 변동 폭
$15.19
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
22.29 | 2.39B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
How To Trade (NAMSW) - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.1%Time to Buy? - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Newamsterdam pharma's COO sells $3.1 million in stock - MSN
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by JPMorgan Chase & Co. - Defense World
Newamsterdam pharma CFO sells shares worth $1.5 million - MSN
Newamsterdam pharma CFO sells shares worth $1.5 million By Investing.com - Investing.com UK
NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference - The Manila Times
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire
Cardiovascular Drug Developer NewAmsterdam Pharma Takes Center Stage at Elite Biotech Conference - StockTitan
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows promise amid trials - MSN
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownHere's What Happened - MarketBeat
Trend Tracker for (NAMS) - Stock Traders Daily
Royal Bank of Canada Reaffirms “Outperform” Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma's (NAMS) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC - Defense World
Analysts Set NewAmsterdam Pharma (NASDAQ:NAMS) Price Target at $39.80 - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $39.80 Consensus Price Target from Analysts - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%What's Next? - MarketBeat
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC Wainwright - MarketBeat
NewAmsterdam Pharma Company N.V. Issues Press Release and Corporate PresentationOn January 10, 2025, NewAmsterdam Pharma Company N.V. filed a Form 8-K with the Securities and Exchange Commission, highlighting significant achievements in 2 - Defense World
NewAmsterdam gears up for obicetrapib regulatory filings By Investing.com - Investing.com Australia
NewAmsterdam gears up for obicetrapib regulatory filings - Investing.com India
NewAmsterdam Pharma Achieves Key Milestones in 2024 - TipRanks
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities - The Manila Times
NewAmsterdam's Cholesterol Drug Achieves Major Breakthroughs: 33% LDL-C Drop in Phase 3 Trials - StockTitan
Geode Capital Management LLC Purchases 1,399 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Grants Equity Awards to New Chief People Officer, Key Hires - StockTitan
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month HighTime to Buy? - MarketBeat
State Street Corp Purchases 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
State Street Corp Buys 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Nap B.V. Forgrowth Sells 29,846 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Brokers Offer Predictions for NAMS FY2024 Earnings - Defense World
FY2024 Earnings Estimate for NAMS Issued By HC Wainwright - MarketBeat
(NAMSW) On The My Stocks Page - Stock Traders Daily
Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock poised for cardiovascular market impact - Investing.com India
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by HC Wainwright - Defense World
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 33,438 Shares of Stock - MarketBeat
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market impact - Investing.com Nigeria
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock poised for cardiovascular market impact By Investing.com - Investing.com South Africa
Newamsterdam Pharma's major shareholders sell shares worth $1.95 million - Investing.com
Obicetrapib’s data positions NewAmsterdam Pharma stock for growth, says H.C. Wainwright - Investing.com Nigeria
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):